N-lower-alkyl and n-substituted-lower-alkyl-n-(and n, n-bis-)[(1-piperidyl)-lower-alkyl]amines



United States Patent Ofitice N-LOWER-ALKYL AND N-SUBSTITUTED-LOWER- ALKYL-N- (AND N,N-BIS-) [(1-PIPERIDYL)-LOW- ER-ALKYL1AMINES Bernard L. Zenitz, Colonie, and Alexander R. Surrey, Albany, N.Y., assignors to Sterling Drug Inc., New York, N.Y., a corporation of Delaware No Drawing. Continuation-impart of application Ser. No. 432,845, Feb. 15, 1965, This application Nov. 25, 1966, Set. N 0. 596,828

18 Claims. (Cl. 260-293) ABSTRACT OF THE DISCLOSURE N-lower-alkyland N-substitutedlower-alkyl-N- (and N,N-bis) [(l-piperidyl)-lower-alkyl]amines, for example N-benzyl-N,N-bis-[3-(4-cyclohexylmethyl-1 piperidyl) propyl]amine, having anti-inflammatory, coronary dilator, hypotensive, anti-fungal, anti-viral, anthelmintic, and psychomotor depressant activities prepared by reduction of the corresponding N-acyl-N-(and N,N-bis-) [(l-piperidyl)-lower-alkyl]amines.

This application is a continuation-in-part of our prior copending application Ser. No. 432,845, filed Feb. 15, 1965, now U.S. Patent 3,325,500, patented June 13, 1967, which in turn is a continuation-in-part of our prior application Ser. No. 129,995, filed Aug. 8, 196l, and now abandoned.

This invention relates to N-lower-alkyland N-substituted-lower alkyl N [(1 piperidyl) lower alkyl] amines, their acid-addition salts, and to processes for the preparation thereof.

Said amines have utility as chemotherapeutic and pharmacodynamic agents of a nature to be more fully described hereinafter.

The compounds of the instant invention are represented by the formula:

ii NY N-R3 R2 lower-alkyl-carbamyl, N,N-di-lower-alkylcarbamyl, piperidinocarbonyl, pyrrolidinocarbonyl, hydroxy, lower-alkoxy, phenoxy, naphthoxy, phenyl-lower-alkoxy, naphthyllower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-loweralkyl, phenoxy-lower-alkyl, naphthoxy-lower-alkyl, loweralkanoylamino, phenyl-lower-alkyl, cycloalkyl-lower-alkyl, or the group R? where R, is phenyl, naphthyl, pyridyl, 3- or 4-piperidyl substituted on the nitrogen atom by lower-alkyl, loweralkanol, phenyl-lower-alkyl, or benzoyl; R is loweralkyl, lower-alkanoyl, phenyl-lower-alkyl, benzoyl, carbamyl, N lower alkylcarbamyl, N,N-di1ower-all ylcarbamyl, or carbo-lower-alkoxy; or R and R taken together with the nitrogen atom to which they are attached form a heterocyclic ring, for example, isoindolinyl, pyrrolidyl, piperidyl, or piperazinyl substituted on the 4- nitrogen atom by lower-alkyl, lower-alkanoyl, phenyl, phenyl-lower-alkyl, or benzoyl; R is hydrogen or .from one to five lower-alkyl radicals; R is phenyl-lower-alkyl, lower-alkyl, cycloalkyl-lower-alkyl, hydroxymethyl-cycloalkylmethyl, phenoXy-lower-alkyl, hydroxy-lowenalkyl,

or cyano-lower-alkyl; Y is loWer-alkylene containing from 3,371,093 Patented Feb. 27, 1968 two to eight carbon atoms and interposing at least two carbon atoms between the amino nitrogen atom of the (l-piperidyl)-lower-all:ylamino group and the ring nitrogen atom of the piperidine nucleus; and n is one of the integers 1 and 2. The variable R in the compounds of Formula I above can also be a divalent alkylene radical joining two of the groupings:

Cl t

together (hereinafter referred to as (l-piperidyD-loweralkylamino radicals), and containing from two to six carbon atoms, for example, 1,2-ethylene, 1,4-butylene, 1,6-hexylene, and the like.

In the above general Formula I, R stands for hydrogen or from one to five lower'alkyl radicals. When R is one or more lower-alkyl radicals, each lower-alkyl radical can be straight or branched and can occupy any of the five available positions on the piperidine ring, and when R is more than one lower-alkyl radical, said radicals can be the same or different and can occupy the same or different positions on the piperidine ring.

As used herein, the terms loWer-alkyl, lower alkoxy, or loWer-alkanoyl mean such groups containing from one to ten carbon atoms which can be either straight or branched and thus represent, inter alia, methyl, ethyl, n-propyl, isopropyl, n-butyl, n-hexyl, methoxy, ethoxy, propoxy, isopropoxy, butoxy hexyloxy, formyl, acetyl, propionyl, isobutyryl, caproyl, decanoyl, and the like.

As used herein, the term cycloalkyl means cycloalkyl containing from three to seven carbon atoms, and thus represents, inter alia, cyclopropyl, cyclobutyl, cyclopentyl. cyclohexyl, or cycloheptyl.

In the above general Formula I, when R or R represent a substituent having a phenyl (or benzyl), or naph thyl, radical, the benzene or naphthalene rings thereof can be unsubstituted or can bear one or more substituents of low molecular weightand of such nature that they do not interfere with or take part in the reactions, to be described hereinafter, used in the preparation of the compounds. Examples of such substituents include halogen, lower-alkyl, loWer-alkoxy, lowenalkylmercapto, loweralkylsulfinyl, lower-alkylsulfonyl, trifiuoromethyl, methylenedioxy, ethylenedioxy, carbo-lower-alkoxy, 2-phenylethoxy, henzyl, lower-alkanoyl, sulfamylL'amino, loweralkanoylamino, lower-alkoxycarbonylamino, lower-alkanoyloxy, hydroxy, and the like. It will be understood that compounds bearing such substituents are the full equivalents of the unsubstituted compounds and are within the purview of the invention.

In the above general Formula I, Y is lower-alkylene containing from two to eight carbon atoms and interposing at least two carbon atoms between the amino nitrogen atom of the (l-piperidyl)-lower-alkylamino group and the ring nitrogen atom of the piperidine nucleus. The loweralkylene group can be straight or branched and thus stands, inter alia, for 1,2-ethylene [CH CH 1,3- propylene [(CH LIZ-(Z-methyIethyIene) 1,4-butylene [(CH 1,5-pentylene [--(CH 1,6-hexylene [-(CH 1,7-heptylene [(CH 1,8-octylene [(CH and the like.

Thecompounds of Formula I where R is phenyl-loweralkyl, lower-alkyl, cycloalkyl-lower-alkyl, hydroxymethylcycloalkylmethyl, phenoXy-loWer-alkyl, hydroxy-loweralkyl, or lower-alkylene and where R, is a non-reducible group are prepared by reducin with an alkali metal aluminum hydride-,the corresponding amides, i.e. the

compounds where R is, respectively, phenyl-lower-alkanoyl (or benzoyl), lower-alkanoyl, cycloalkyl-lower-alkanoyl, carboxy-cycloalkylcarbonyl, phenoxy-lower-alkanoyl, carboxy-lower-alkanoyl, or a divalent residue of a dibasic carboxylic acid. The reaction is carried out at a temperature in the range from C. to about 65 C. in an organic solvent inert under the conditions of the reaction, for example, dioxane, tetrahydrofuran, diethyl ether, dibutyl ether, and the like. A preferred reducing agent is lithium aluminum hydride.

The compounds of Formula I where R;, is phenyllower-alkanoyl (or benzoyl), lower-alkanoyl, cycloalkyllower alkanoyl, carboxy cycloalkylcarbonyl, phenoxylower alkanoyl, carboxy lower alkanoyl, or a divalent residue of a dibasic carboxylic acid and which are required as intermediates for the preparation of the compounds where R is, respectively, phenyl-lower-alkyl, lower alkyl, cycloalkyl lower alkyl, hydroxymethylcycloalkyl methyl, phenoxy, lower alkyl, hydroxylower alkyl, or lower alkylene are prepared by reaction of the compounds of Formula 11 having the formula ig N- -NH R. I.

and where R R Y, and n have the meanings given above with the corresponding acid halide. The reaction is preferably conducted in an organic solvent inert under the conditions of the reaction, for example, benzene, toluene, xylene, dioxane, and the like, and at a temperature in the range from 50 C. to 150 C. The reaction can, if desired, be carried out in the presence of an acidacceptor to take up the hydrogen halide split out during the course of the reaction. Suitable acid-acceptors are alkali metal hydroxides, for example, sodium or potassium hydroxide, alkali metal carbonates or bicarbonates, for example, sodium or potassium carbonate or sodium or potassium bicarbonate, or an excess of the amine starting material.

Another method for preparing the compounds of Formula I where R is phenyl lower alkanoyl (or benzoyl), lower alkanoyl, carboxy cycloalkylcarbonyl, or a divalent residue of a dibasic carboxylic acid, and which can also be used to prepare the compounds of Formula I where R is carboxy-lower-alkanoyl comprises reacting the secondary amines of Formula II with the corresponding acid anhydride. The reaction is preferably conducted in an organic solvent inert under the conditions of the reaction, for example, benzene, toluene, xylene, dioxane, and the like, and at a temperature in the range from C. to 150 C. The reaction is preferably carried out in the presence of a basic catalyst for example, pyridine or triethylamine.

The compounds of Formula I where R is methyl can also be prepared by reductive alkylation of the amines of Formula II with formaldehyde and formic acid using the .Eschweiler-Clarke modification of the Leuckart reaction. The reaction is preferably conducted in an excess of formic acid as the solvent at the reflux temperature thereof.

Another method of preparing the compounds of Formula I where,R is phenyl-lower-alkyl comprises reacting the secondary amines of Formula II with a phenyllower-alkyl halide. The reaction is preferably conducted in an organic solvent inert under the conditions of the reaction, for example, benzene, ethanol, methanol, and the like, at a temperature in the range from 50 C. to 150 C. The reaction is preferably carried out in the presence of an acid-acceptor to take up the hydrogen halide split out during the course of the reaction. Suitable acid-acceptors are alkali metal carbonates and bicarbonates, for example, sodium or potassium carbonate or sodium or potassium bicarbonate, or alkali metal hydroxides, for example, sodium or potassium hydroxide.

An alternative method for preparing the compounds of Formula I where R is 2-hydroxyethyl comprises reacting the amines of Formula II with ethylene oxide. The reaction is preferably conducted in an autoclave at temperatures in the range from to 250 C. and in an organic solvent inert under the conditions of the reaction, for example, benzene, toluene, lower-alkanols, and the like.

The compounds of Formula I where R is cyanolower-alkyl are prepare/.1 by reacting the compounds of Formula II with a cyano-lower-alkyl halide in the presence of an acid-acceptor and at temperatures in the range from 50 to C. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example, methanol, ethanol, benzene, toluene, and the like. The purpose of the acid-acceptor is to take up the hydrogen halide which is split out during the course of the reaction and can be any basic substance which forms water-soluble salts easily separable from the reaction mixture. Suitable acid-acceptors are alkali metal hydroxides, for example, sodium or potassium hydroxide, alkali metal carbonates or bicarbonates, for example, sodium or potassium carbonate or sodium or potassium bicarbonate, and the like.

Alternatively the compounds of Formula I where R is 2-cyanoethyl can be prepared by reacting the compounds of Formula II with acrylonitrile. The reaction is carried out in an organic solvent inert under the conditions of the reaction, for example, benzene, toluene, methanol, acetone, and the like. It is preferred to conduct the reaction in an excess of the acrylonitrile at the boiling point thereof.

The intermediate monoand his [(1 piperidyl) lower-alkyl]amines of Formula II are prepared by reducing, with hydrogen in the presence of a catalyst, a 1- (cyano-lower-alkyl)piperidine having the formula III where R and R have the meanings given above; and Y is lower-alkylene containing from one to seven carbon atoms and interposing at least one carbon atom between the ring nitrogen atom of the piperidine nucleus and the cyano group.

The reduction of the compounds of Formula III is carried out in an organic solvent inert under the conditions of the reaction, for example, methanol, ethanol, or 1sopropanol, at a temperature in the range from about 20 C. to about 70 C. and at hydrogen pressures in the range from about 40 pounds p.s.i. to about 1,000 pounds p.s.i. When the reduction is carried out in a neutral medium, the bis-[(1 piperidyl)-lower-alkyl]amines of Formula II (n is 2) are the predominant products although the mono-[(1 piperidyl) lower alkyl]amines (n is l) are also produced. On the other hand, if the solvent used is first saturated with anhydrous ammonia, so that the reaction medium is strongly ammoniacal, the predominant products are the mono [(1 piperidyl)- lower alkylJamines, although the his [1 piperidyl)- lower-alkyllamines are also produced in minor amounts. Suitable catalysts are platinum oxide, palladium-oncharcoal, and rhodium-on-alumina. A preferred catalyst is rhodium-on-alumina.

The l-(cyano-lower-alkyl)piperidines of Formula III are disclosed in and are prepared by methods described in our US. Patent 3,262,936 (patented July 26, 1966). These methods comprise, for example, reacting on acrylonitrlle with a piperidine in the presence of a basic catalyst, a method used for the preparation of the compounds where Y is lower-alkylene interposing two carbon atoms between the cyano group and the ring nitrogen atom of the piperidine nucleus. The reaction is represented by the equation:

where R and R have the meanings given above and each of R and R" stands for hydrogen or the methyl radical, or one of R' and R" is hydrogen while the other is the ethyl radical. The reaction is preferably carried out in a solvent inert under the conditions of the reaction, for example, water, benzene, dioxane, pyridine, or acetonitrile. A preferred solvent is water. Suitable basic catalysts are tri-lower-alkylamines, for example, triethylamine, or basic tertiary heterocyclic amines, for example, pyridine, or quaternary ammonium hydroxides, for example Triton B (benzyl trimethylammonium hydroxide). A preferred basic catalyst is triethylamine.

The compounds of Formula III where Y is loweralkylene interposing from one to seven carbon atoms between the cyano group and the ring nitrogen atom of the piperidine nucleus are prepared by'reacting a cyano-loweralkyl halide with an appropriate substituted-piperidine in the presence of an acid-acceptor. The reaction is preferably carried out in an organic solvent inert under the conditions of the reaction, for example, tetrahydrofuran, acetone, methanol, ethanol, isopropanol, and the like. The purpose of the acid-acceptor is to take up the hydrogen halide split out during the course of the reaction and is a basic substance which forms water-soluble by-products easily separable from the main product of the reaction and includes such substances as alkali metal salts of weak acids, e.g. sodium carbonate, sodium bicarbonate, potassium carbonate, sodium acetate, and the like. The acidacceptor can also be in the form of an excess quantity of the substituted-piperidine.

The novel compounds of the instant invention are the compounds of Formula I and their acid-addition salts. The compounds of Formula I, in free base form, are converted to the acid-addition salt form by interaction of the base with an acid. In like manner, the free bases can be regenerated from the acid-addition salt form in the conventional manner, that is, by treating the salts with strong aqueous bases, for example, alkali metal hydroxides, alkali metal carbonates, and alkali metal bicarbonates. The bases thus regenerated can then be interacted with the same or a different acid to give back the same or a different acidaddition salt. Thus the novel bases and all their acid-addition salts are readily interconvertible.

It will thus be appreciated that Formula I not only represents the structural configuration of the bases of the invention but is also representative of the structural entity which is common to :all of our compounds of Formula 1, whether in the form of the free bases or in the form of the acid-addition salts of the bases. We have found that by virtue of this common structural entity, the bases and their acid-addition salts have inherent pharmacodynamic and chemotherapeutic activity of a type to be more fully described hereinbelow. This inherent pharmacodynamic and chemotherapeutic activity can be enjoyed in useful form for pharmaceutical purposes by employing the free bases themselves or the acid-addition salts formed from pharmaceutically-zacceptable acids, that is acids whose anions are innocuous to the animal organism in effective doses of the salts so that beneficial properties inherent in the common structural entity represented by the free bases are not vitiated by side-effects ascribable to the anions.

In utilizing this pharmacodynamic activity of the salts of the invention, We prefer of course to use pharmaceuticallyacceptable salts. Although water-insolubility, high toxicity, or lack of crystalline character may make some particular salt species unsuitable .or less desirable for use as such in a given pharmaceutical application, the waterinsoluble or toxic salts can be converted to the corre- 6 sponding pharmaceutically-acceptable bases by decomposition of the salt with aqueous base as explained above, or alternatively, they can be converted to any desired pharmaceutically-acceptable acid-addition salt by double decomposition reactions involving the anion, for example, by ion-exchange procedures.

Moreover, apart from their usefulness in pharmaceutical applications, our salts are useful as characterizing or identifying derivatives of the free bases or in isolation or purification procedures. Like all of the acid-addition salts, such characterizing or purification salt derivatives can, if desired, be used to regenerate the pharmaceuticallyacceptable free bases by reaction of the salts with aqueous base, or alternatively can be converted to a pharmaceutically-acceptable acid-addition salt by, for example, ionexchange procedures.

It will be appreciated from the foregoing that all of the acid-addition salts of our new bases are useful and valuable compounds, regardless of considerations of solubility, toxicity, physical form, and the like, and are accordingly within the purview of the instant invention.

The novel feature of the compounds of the invention, then, resides in the concept of the bases and cationic forms of the new N-lower-alkyland N-substituted-lower-alkyl- N-[(l-piperidyl)-lower-alkyl]amines and not in any particular acid moiety or acid anion associated with the salt forms of the compounds; rather, the acid moieties or anions which can be associated in the salt forms are in themselves neither novel nor critical and therefore can be any acid anion or acid-like substance capable of salt formation with bases. In fact, in aqueous solutions, the base form or water-soluble acid-addition salt form of the compounds of the invention both possess a common protonated cation or ammonium ion.

Thus the acid-addition salts discussed above and claimed herein are prepared from any organic acid, inorganic acid (including organic acids having an inorganic group therein), or organo-metallic acid as exemplified by organic monoand poly-carboxylic acids; such as found, for example, in Beilsteins Organische Chemie, 4th ed., volumes III, IV, IX, X, XIV, XVII, XIX, XXI, XXII, and XXV; organic monoand poly-sulfonic and -sulfinic acids; such as found, for example, in Beilstein volumes VI, XI, XVI, and XXII; organic phosphonic and phosphinic acids; such as found, for example, in Beilstein volumes XI and XVI; organic acids of arsenic and antimony; such as found, for example, in Beilstein volume XVI; organic heterocyclic carboxylic, sulfonic, and sulfinic acids; such as found, for example, in Beilstein volumes XVIII, XXII, and XXV; acidic ion-exchange resins; and inorganic acids of any acid-forming element or combination of elements, such as found in Mellor, Comprehensive Treatise on Inorganic :and Theoretical Chemistry. Longmans Green and Co., New York, N.Y. volumes I-XVI. In addition, other salt-forming compounds which are acidic in their chemical properties, 'but which are not generally considered as acids in the same sense as carboxylic or sulfonic acids, are also considered to be among the numerous acids which can be used to prepare acid-addition salts of the compounds of the invention. Thus there is also comprehended acidic phenolic compounds, such as found, for example, in volume VI of Beilstein, acidic compounds having activated or acidic hydrogen atoms, as for example, picrolonic acid, or barbituric acid derivatives having an acidic proton, such as found, for example, in Cox et al., Medicinal Chemistry vol. IV, John Wiley and Sons, Inc., New York, N.Y. (1959). Also comprehended as salt forming agents are so-called Lewis acids which lack a pair of electrons in the outer electron shell and react with basic compounds having an unshared pair of electrons to form salts, for example, boron trifluoride.

Thus appropriate acid-adidtion salts are those derived from such diverse acids as formic acid, acetic acid, isobutyric acid, alpha-mercaptopropionic acid, malic acid,

furnaric acid, succinic acid, tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnamic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, 2-pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, benzenesulfonic acid, p-toluenesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphinic acid, p-an'linophenylarsinic acid, phenylstibnic acid, phenylphosphinous acid, methylphosphinic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphoinolybdic acid, pyrophosphoric acid, arsenic acid, picric acid, picrolonic acid, barbituric acid, boron trifluoride, and the like.

The acid-addition salts are prepared either by dissolving the free base in an aqueous solution containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

Pharmacological evaluation of the compounds of Formula I have shown that they possess pharmacodynamic and chemotherapeutic properties, in particular, anti-inflammatory, coronary dilator, hypotensive, anti-fungal, anti-viral, anthelrnintic, and psychomotor depressant activities thus indicating their usefulness as anti-inflammatory, anti-fungal, anti-viral, and blood pressure lowering agents, coronary dilators, anthelmintics, and tranquilizers.

The structures of the compounds of the invention are established by their mode of synthesis and corroborated by the correspondence between calculated values for the elements and values found by chemical analysis.

The following examples will further illustrate the invention without the latter being limited thereto.

EXAMPLE 1 3 (4 carbamyl I piperidyl)propylamine [lI: R is 4-CONH R is H; Y is (CH n is 1] To a solution of 34.75 g. (0.19 mole) of 1-(2-cyanoethyl)-4-carbamylpiperidine in 450 ml. of ethanol saturated with anhydrous ammonia was added 4.2 g. of a 5% rhodium-on-alumina catalyst. The mixture was reduced with hydrogen under an initial pressure of 210 pounds psi. at a tempearture of 25 C. Reduction was complete in three hours. The catalyst was removed by filtration, washed with ethanol, the filtrate concentrated to dryness in vacuo and the white crystalline residue extracted with acetone, filtered, andthe filtrate taken to dryness yielding 25.4 g. of a white powder which was recrystallized twice from a benzene-hexane mixture giving 22.0 g. of 3-(4- carbamyl 1 piperidyl)propylarnine, M.P. 85-88 C. uncorr.).

EXAMPLE 2 (a) 1-(5-cyanopentyl) 4 cyclohexylmethylpiperidine (55.3 g, 0.2 mole) was dissolved in 250 ml. of ethanol and reduced over 4.5 g. of a rhodium-on-alumina catalyst under 60 pounds p.s.i. of hydrogen. When reduction was completed, the catalyst was removed by filtration and the residue distilled in vacuo, all material (22.7 g.) boiling at 117-128 C./0.046-0.055 mm. being collected as 6-(4- cyclohexylmethyl 1 piperidyl) hexylamine. A small amount of the latter in isopropanol was converted to the dihydrochloride salt and recrystallized twice from ethanol-acetone to give 6-(4-cyclohexylrnethyl-1piperidyl) hexylamine dihydrochloride, M.P. 231.6-236.2 C.

Analysis.-Calcd. for C I-l N 2HCl: C, 61.17; H, 10.84; Cl, 20.07. Found: C, 61.20; H, 10.71; Cl, 19.63.

(b) The pot residue remaining after distillation of the primary amine was recrystallized several times from acetone-ethanol to give 26.6 g. of N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyDhexyl]amine, M.P. 5 3.554.5 C.

Analysis.-Calcd. for C H N C, 79.49; H, 12.79; N, 7.72. Found: C, 79.33; H, 12.73; N, 7.59.

EXAMPLES 3-17 The following mono-l:(l-piperidyl)-lower-alkyl]amines of Formula II [n is 1; R is H] listed below in Table 1 are prepared according to one of the procedures described above in Examples 1 or 2 by reduction of an appropriate 1-(w-cyano-lower-alkyl)piperidine of Formula III with hydrogen over a rhodium-on-alumina catalyst. All melting points are corrected.

TABLE 1 Ex. R Y Base or M.P. C.) Cryst. from- Salt 3. 4-0 ONHCH; (CHm 21101 239. 6-240. 6 Ethanol/ether. 4.--- 4-CONYC H (CH2); 2HCl 245. 0-2462 Do. 5.-.- 4-CON(CH3)2 (CH2): Base 1 6...- 4-CON(C2H5)Z (CHm -do..- 2 7.--. 4C1I2C6H5 (CH2): 2HCl 191. 6193.4 Do. 8. 4-CHzC6Hn (C1193 ZHCl 280. 2-282. 4 Do. 9.... 4-110 (CHm Base. 10. 4-110 (C1103 (C1103 .do... 163. 13-165. 2 Isopropanol. 11 d-(CHa) zCH C1193 211 C1 215. 2-217. 8 D0. 12.-- B-CI-I CONH (CH1): Base. 13. 4-CI-IgC6Hn (CH2): ZHCI 259. 8-262. 8 Ethanol/acetone. 14. 2-CH2C5H11 (CH2); 21101 2000-20618 Isopropanol. 15 l-GHzCaIIn (CHM 2HC1 2152. 8-266. 0 Do. 16.-. 441112631111 (CHEM ZHCl 250. 6-2572 D0. 17. 4-CHzCeH11 (CH2) 1 2H Cl 2410-2406 Acetone.

1 B.P. 123-124 C./0.09 111111.; 'n =1.5042.

2 B.P. 131-138" C./0.109-0.113 111111.; n =1.4938. 3 B.P. 85.3-86.8 C./0.033 111111.; 77.1) =l.5058.

EXAMPLES 18-3 3 The following N,N bis [(l-piperidy-l)-lower-alkyl] amines of Formula II [n is 2; R is H] listed below in Table 2 are prepared according to one of the procedures described above in Examples 1 or 2 by reduction of an appropriate l-(w-cyano-lower-aikyl)piperidine of Formula 111 with hydrogen over a rhodium-on-alurnina catalyst. All melting points are corrected.

TABLE 2 Ex. R1 Y Base 0r M.P. C.) Crystd. from Salt 18. 4-CONH CH3 (CH2); Base 203. 0-203. 8 Ethanol/ ae t 19. 4CONI'IC2H5 (CHzh .do..- 191. 2-192. 8 8 one 20. 4-CON (CH0: (CH2); -do..- 87. 8-88 6 Hexane 21 4-CHzC6H (GH:)3 3H Cl 266. 6-260 0 Ether. 22. 4-CHgCsH11 (CH2)3 3HC1 300 Isopropanol/ th 23... 4-(CH3)2CH (C1193 Base. 6 er i ii rcrt) i i 2 2 a 2 s 3H Cl 191. 2-199. 4 ro anol.

26- 4-CHzCt5Hn (CH1); BHCI 294. 4-298. 2 Etl an l. 27. 4-CHzCtHn (CH2); Base 37. 2-43. 0 Acetone. 28. 2-CH2CGH11 (CH1); 35101 179. 2-192. 4 Do. 29. d-CHzCuH (CH;)4 Base 50. 2-51. 0 Do. 30. 4-CHzCsH11 (CH2) .do.- 57. 2-58. 5 D0. 0].... 40111051111 (Cl-I9 .-do.- 63. 6454.4 DO.

I 32. 4-CH N CO CH (CH2); 3H C1 247. 8-251. 0 Methanol} l acetone. 33. 4-C6H5N CH (CH2)@ 3H2O 88-100 Acetone/water.

1 B.P. l25.5131.( C./0.0015 mm.; nn =1.4832. Trihydrochloride, recrystallized from lsopropanol, gave M.P. 291.2293.4 C. (corn).

2 13.1. 186-193 C./0.002-0.0024 1pm.; m1 =1.5197.

EXAMPLES 34-74 By following the manipulative procedure described above in Example 1, substituting for the 1-(2-cyanoethyl)-4-carbamyl-piperidine used therein, a molar equivalent amount of an appropriate l-(cyano-lower-alkyD- substituted-piperidine, there can be obtained, the (subis 1) listed below in Table 3.

TABLE 3 H H H H H H H H u s H 4-(2-naphthyl-O) H CH 4OH5CH CHO H (OHm.-- 4-(2-naphthyl-CH H H (CH2)a- 3- 1130 H (CHM.-- 4-C2H50(CH2)3 H (0H,-.- 3-(4-C106H4OCH2CH2 H 2)s--- D Y 2)2] H I v ((3112):.-- 4-CaHsNCHz H I (OHz); 4-CaH5NCOCH3 H I (GH2)3--- 4-C5H5NOH2CH2CQH5 H I (CH2)4.-- 4-C5H5NCOC0H5-.. H (CH2)1--- zmaphthyl-NCH u H (CH,) 4-(4-CI5H4N)NCH H (CH2)z. 4(1-methy1-?rp1per1dy1)NCH3- H CH 4-(1-acetyl-3-piperidyIZNCH3 H (CHa)a 4 (l-phenethyl-El-pipendyl)NCH H (CH2)a 4-(1-benz0yl-3-piperidyDNCH I (CHm--- 4-CBH5NCONH2 H 64 (CHM.-- 4C@H5NCONH OH I 65- (GH:)s 4-C0H5NCON(CH3)2 H v I I 4-C5H5NCOOC3H5 H 4-(2-isoindo1inyl) H 4-(1-py1rolidyl) H 4(1-piperidyl) a- H 4 (fi-methyl-l-piperazinyl) H 4-(4-acetyl-1-piperazinyl) H 4-(kphenyl-l-piperazinyl) H 4-(4-phenethyl-l-piperaziuy H 4-(4-benzoyl-1-piperazinyl) H EXAMPLES 75-113 'of Formula II (n is 2) listed below in Table 4.

TABLE 4 4-CHaOH :OEZOHZCHEOHL Example m mmmmmtummmmmmmmssemm E (CH2)3 4-C eHsNCHaCHzCaHs 94- (CH2)2- 2-naphthyl-NOH r)a -(4 aH4 C a. (GHr)a 4-(1-methyl-3-piperidyDNCH3. (OHz)a- 4-(1-acetyl-3-piperidyl)NCH3 (CH2)a 4-(l-phenethyl-ii-piperidyDNCH; (CHM. 4-(1-benzoyl-3-piperidyl)NCHz.

I (C1193.-- 4-CH5NCONH2 I 103 (01193;- 4-CIH5NCONHOH I 104 (0112);..- 4-C6H5NCON(CH3)2 I 4-0 aHsNCOOCzHs. 4-(2-isoindo1iny1) t-(l-pyrrolidyl) 4- (l-piperidyl) 4-(4-methyl-1-piperazinyl) 4-(4-acetyl 1 piperazinyl) 4-(kphenyl-l-piperazinyl) 4-(4-phenethyl-1-piperazinyl) 4-(4-b enzoyl-l-piperazinyl) MI II UI IIII'F II II II I II I I I I mmmmmmm EXAMPLE 114 N benzoyl-N,N-bis-[3-(4-cycl0hexylmethyl-1-piperidyl) propyl]amine dihydrochloride [1: R is 4-CH C H R is H; R is C H CO; Y is (CH n is 2] The following N-(R )-N,N-bis-[(4-cyclohexylrnethyl- 1-piperidyl)-lower-alkyl]amines of formula I (R is 4- CH C HH; R is H; n is 2] listed below in Table 5 were .prepared using the procedure described above in Example 112 by reaction of an appropriate acid chloride with an appropriate N,N bis[(4-cycloheXylmethyl-1-piperidyl)- lower-alkyl] amine. All melting points are corrected.

TABLE 5 Example Y R Base or Salt Ml. C.) Cryst. from- C H5CO 41.2-42.6 Acetone. 2-CICGH4CO 241. 2- 243.0 Isopropanol/acetone. 4-ClC6H4CO 54. 6-55. Acetone. 3,4-Cl2CaH3CO 179. 4-182. 8 Do. 401130031110 245. 2-246. 0 Ethanol/acetone. 4011300311400 202. 4-206. 2 Do. 3-CF3COH4CO. 231. 0-231. 8 Isopropanol.

-CF.1C H4C O 195. 4-198. 0 Acetone/ether. (CH3)2CHCO 192. 6-196. 0 Ethanol/acetone. CI3 QH2 EC O 185. 0-187. 4 Methanol/acetone. CH3(UH2)3CO 181. 0-185. 0 Acetone. (CHmC HCHZCO 180. 4-184. 8 Acetone/ether. CH3(GI{2) 3C0 130. 4-134. 0 Acetone. CHa(CI-IZ)4CO 181. 8-183. 6 Do. 011 10119 00 178. 0-184. 0 Acetone/ethyl acetate. CHa(CH )5CO 191. 6-194. 6 Ethanol/ether.

105. 6-201. 2 Ethanol/acetone/ether. 224-226. 5 Methanol/acetone. 187. 0-189. 2 Chloroiorm/ethyl acetate.

59. 2-63. 4 Acetone. 55. 2-504 D0. 97.6-90.2 Do. 258. 0--61. 0 Methanol/acetone/ether. 107. 0-190. 8 Ethanol/acetone.

. Acetone. (CHM... Ethanol/acetone. (011m. Ethanol/acctone/ether. (CH;)6 Methanol/acetone/ether. (CI-I91... Do. (CHM. Acetone/other. (Cl-1m. Acetone. (CHM... 3,5-(NO2)2 Methanol/acetone. (CH1 3-N0g-4Cl-C H3C Acetone. (CHM... 3-Cl-5-H0-C3H3OO Methanol/ether. (CH )5 Acetone/ether. (CHM... Hexane. (CHM... Acetone. (CHM. Hexane. (01101." Acetone.

Bis-cyclohexanesuliainate salt.

TABLE 6 Ex. Y R3 Base at M.P. Cryst. Salt C. from- 156 (CH2); CHSCO Base 59.2 -61.0 Hexane. 157.. (0112):; CHaCO 2HCl 258.8262.8 Egianol/ e mi. 158.. ((3111).; CHzCO 2HCl-H O 2458-2416 Do. 150. (CH:)1 011300 2HCl 237.6238.8 Isopropanol/ acetone.

160-- (CH1); CHzCHzOO-.. 21-101... 235.2-237.4 Ethanol} acetone/ ether. 161.- (CH1); CH CHzGO... 2HC1 226.0227.8 Ethanol] acetone. 162-. (CHm 011303100... 21101... 227.2-228.6 Methmol/ ace one. EXAMPLE 155 163-- (CH1): cnaonmco 2H01..-. mas-203.4 Ethanol] acetone. N acetyl N,N-bis[3-(4-cycl0hexylmethyl-I-pzperzdyl) (CHm CH3(CH1)=CO 21101 2260-2311) ggg' gg pr0pyl]-amine dihya'rochlorzde [1: R 15 4-CH C H11; 165-- (CHM CHa(CH2)nCO 2HO1 201.8203. 2 Methanol] R 18 H; R 18 cn co; Y 15 (CH2)3;H1S 2]. gggggf 166-- (CHM CH3 CH2 2CO 2HC1 2008-20724 Acetone.

A solution of 13.8 g. (0.03 mole) of N,N-bis-[3-(4- cyclohexylmethyl-l-piperidyl) pr0pyl1amine, 4 g. (0.04 mole) of acetic anhydride, and 50 ml. of pyridine was allowed to stand overnight at room temperature and then warmed one hour on a steam bath. The mixture was taken to dryness in vacuo; the residual oil was dissolved in 100 ml. of benzene and the solution washed once with dilute potassium carbonate, several times with water, and taken to dryness. The residual oil was distilled in vacuo, the fraction boiling at 203-210 C./0.002 mm. (n =1. 5062) being collected as product.

A small amount of the oil, converted to the hydrochloride salt and recrystallized from absolute ethanol, gave N acetyl N,N-bis-[3-(4-cyclohexylmethyl-l-piperidyl) propyl] amine dihydrochloride, M.P. 2772-2790 C. (corn).

EXAMPLES 156-166 peridyl)-lower-alkyl]amine. All melting points are corrected.

EXAMPLE 167 N ([3 carboxypi'op ionyl) N,N bis-[3-(4-cycloheqcylmethyl-I-piperidyl')-propyl]amine dihydrochloride [1: R1 is 4-CH2CGH11; R2 iS R3 is Y is n is 2].

A mixture of 11.6 g. (0.025 mole) of N,N-bis-[3-(4- cyclohexylmethyl-1-piperidyl)propyl]amine and 2.65 g. (0.026 mole) of succinic anhydride in about 200 m1. of benzene was heated under reflux using a water separator for three hours and then taken to dryness. The residual gum was dissolved in acetone and reprecipitated by addition of hexane, the process being repeated three times, and the remaining gummy material was then dissolved in a small volume of ethanol and acidified by addition of excess ethanolic hydrogen chloride. Precipitation of the resulting salt by addition of ether and recrystallization of the precipitate from acetone/methanol gave 6.2 g. of N- 18 carboxypropionyl -N,N-bis- 3 (4-cyclohexylmethyll-piperidyl)propyl] amine dihydrochloride, M.P. 239 C. (-dec., corr.).

EXAMPLE 168 N (f3 carboxypropionyl) N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl)hexyl]amine dihydrochloride {1: R is N (2 carboxycyclohexylcarbonyl) N,N-bis-[6-(4- cyclohexylmethyl l-piperidyl)hexyl]-amine dihydrochloride R1 is 4-CH2C Hfl R2 is R3 is Y is (CH n is 2] was prepared from 16.3 g. (0.03 mole) of N,N-bis-[6-(4-cyclohexylmethyl-1- piperidyl) hexyl]amine and 5.55 g. (0.036 mole) of 1,2-cyclohexanedicarboxylic anhydride in about 100 ml. of benzene using the manipulative procedure described above in EX- ample 167. The product was isolated in the form of the dihydrochloride salt and the latter recrystallized from acetone to give 6.1 g. of N-(2-carboxycyclohexylcarbonyl) N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl)hexyl] amine dihydrochloride, M.P. 235.0-235.5 C. (corr).

EXAMPLE 170 N- (,6 p/zenylpropionyl)-N,N-bis-[3-(4-cyclohexylmethyl-Lpiperidyl)-prpyl1amine dihydrochloride [1: R is 4CI I2C6H11; R2 is R3 is Y is (CI-1 h; n is 2].

N cinnamoyl N,N-bis-[3-(4-cyclohexylmethyl-l-piperidyl)propyl]amine (12.6 g., 0.026 mole) was dissolved in about 200 ml. of absolute ethanol and reduced over 1.0 g. of palladium-on-charcoal catalyst under hydrogen at sixty pounds p.s.i. pressure. Reduction was complete in about two and a half hours, and the mixture was filtered from the catalyst, and the filtrate taken to dryness giving 11.4 g. of a pale yellow viscous oil. The latter was dissolved in ml. of ether, and the solution treated with excess ethanolic hydrogen chloride. The solid which separated was collected, washed with ether and recrystallized from an ethanol/acetone mixture giving 8.9 g. of N-(flphenylpropionyl) N,N bis [3-(4-cyc1ohexylmethyl-1- piperidyl)propyl]amine dihydrochloride, M.P. 257.5- 259.0 C. (corr.).

EXAMPLE 171 N 8 phenylpropionyl) N,N-bis-[6-(4cyclohexylmethyl-1-piperidyl)hexyl]amine dihydrochloride [Iz R is 4-CHZCSH11; R2 is R3 is Y is (CH n is 2] was prepared by catalytic reduction of 14.9 g. (0.02 mole) of N-cinnamoyl-N,N-bis-[6-(4-cyclo- -hexylmethyl-l-piperidyl)hexyl]arnine in 200 ml. of ethanol over 1 g. of palladium-on-charcoal catalyst using the manipulative procedure described above in Example 170. The crude product, converted to the dihydrochloride salt, was recrystallized from an ethanol/acetone mixture giving 9.1 g. of N-(B-phenylpropionyl)N,N-bis[6-(4cyclohexylmethyl 1 piperidyl)hexyl]amine dihydrochloride,

M.P. 185.8-1876" C. (corr.).

EXAMPLE 172 14 filtered from the catalyst, and the filtrate diluted with 250 ml. of acetone and cooled. The solid which separated was collected, washed with ether and recrystallized from an ethanol/acetone mixture giving 9.3 g. of N-(B-cyclohexylpropionyl) N,N bis-[3-(4-cyclohexylmethy1-l-piperidyl)propyl]amine dihydrochloride, M.P. 236-240 C. (corr.).

EXAMPLES 173-176 The following N (e-cyclohexylpropionyl)-N,N-bis- 4-cyclohexylmethyl-l-piperidyl)-lower-alkyl] amines of Formula I (R is 4-CH C H R is H; R, is

C H CH CH CO n is 2] listed below in Table 7 were prepared by reducing over platinum oxide the corresponding N-cinnamoyl-N, N bis [(4-cyclohexylmethyl-l-piperidyl)-lower-alkyl] amines using the manipulative procedure described above in Example 172.

TABLE 7 Ex. Y Base or M.P. C.) Cryst. from Salt 173- (CHm. 2H C1 229. 5-231. 0 Acetone/ethyl acetate. 174" (CHQ 2HCl 211. 0-214. 0 Ethanol/acetone. 175. (OHM... 2HCl. 182. 2-184. 0 Ethanol/acetonc/ether. 176- (CHz) 2HC1 195-197 Ethanol/ether.

EXAMPLE 177 N-(Z-aminobenmyl) -N,N-bis-[3- (4 cyc'lohexylmethyl-J- piperidyl)-pr0pyl]amine trihydrochloride [I2 R is 4"CH2C6H11; R2 iS R3 is 2-NH C H CO; Y is 2)3; I1 is A mixture or" 11.6 g. (0.02 mole) of N,N-bis-[3-(4- cyclohexylmethyl-1-piperidyl)propyl]amine and 4.4 g. (0.03 mole) of isatoic anhydride in about ml. of benzene was heated under reflux for three hours and then taken to dryness. The residue was dissolved in 200 ml. of methanol, cooled overnight in a cold room, and the solid material which separated was collected to give 6.1 g. of N (2 carboxyphenylaminocar-bonyl)-N,N-bis-[3,(4- cyclohexylmethyl-1-piperidyl)propyl] amine as a by-product. Concentration of the filtrate to a small volume and further cooling afforded a second crop of 1.0 g. of the same byproduct.

The filtrate obtained after collection of the above-named by-product was concentrated to a small volume, acidified with 6.0 ml. of 7.33 N ethanolic hydrogen chloride, diluted strongly with ether, and the hydrochloride salt which separated was collected and dried to give 7.2 g. of crude material.

The latter was dissolved in chloroform and reconverted to the free base by washing with dilute sodium carbonate and water and drying the chloroform solution containing the free base over anhydrous calcium sulfate. The solution was then rendered 2% in isopropylamine by addition of 6.0 ml. of the latter and treated three times with stirring for fifteen minutes with 5.0, 10.0, and 15.0 g. batches of silica gel, filtering the solution each time the adsorbent.

The solution was then taken to dryness once again, the residue was dissolved in absolute ethanol, and the solution acidified with excess ethanolic hydrogen chloride. Dilution of the solution with acetone and ether caused the separation of a solid material which was collected and recrystallized from isopropanol/ acetone to give 3.4 g. of N (Z-aminobenzoyl)-N,N-bis-[3-(4-cyclohexylmethyl- 1-piperidyl)propyl]amine trihydrochloride, M.P. 240.0- 260.0 C. (indef., corr.).

EXAMPLE 178 15 N (4 nitrobenzoyl)-N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl)hexyl] amine dihydrochloride (10.8 g., 0.014 mole) was dissolved in 250 ml. of absolute ethanol and reduced over 0.2 g. of platinum oxide catalyst under an initial hydrogen pressure of 60 pounds p.s.i. at room temperature. After an uptake of the theoretical amount of hydrogen, the catalyst was removed by filtration, and the filtrate evaporated to a volume of about 50 ml. The solid which separated on cooling was collected and dried giving 3.2 g. of N-(4-aminobenzoyl)-N,N-bis[ 6-(4-cyclohexylmethyl-l-piperidyl)hexyl]amine dihydrochloride,

M.P. 241.-6243.0 C. (corr.).

EXAMPLE 179 N-(3,5-diaminobenzyl)-N,N-bis-[6-(4 cyclohexylmezh- 1 yl-l-piperidyl)hexyl]amine dihydrochloride [1: R is 4-CH C H R2 is R3 iS 3,5-(NH2)2C6H3CO; Y iS 2)s; is

N-(3,5-dinitrobenzoyl N,N bis [6-(4 cyclohexyl methyl-l-piperidyl)hexyllamine dihydrochloride (19.1 g., 0.024 mole) was dissolved in 250 ml. of ethanol and reduced over 0.6 g. of platinum oxide catalyst under an initial hydrogen pressure of 60 pounds p.s.i. and at a ternperature of from 28 to 42 C. After a total uptake of the theoretical amount of hydrogen, the catalyst was removed by filtration, and the filtrate evaporated to a small voltime and cooled. The solid which separated was collected and dried giving 5.5 g. of N-(3,5-diarninobenzoyl)-N,N- bis-[6-(4-cyclohexylrnethyl-l-piperidyl) hexyl] amine dihydrochloride, M.P. 250.0252.0 C.

EXAMPLE 180 N-(3-amin0 4 chlorobenzoyl) N,N bis-[6-(4-cycl0- hexylmethyl-1piperidyl)hexyljamine dihydrochloride [1: R1 is 4-CH2C6H11', R2 is R3 is 3-NH2-4-C1C6H3CO; Y iS n is N (3 nitro 4 chlorobenzoyl)-N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl)hexyl]amine dihydrochloride (21.7 g., 0.03 mole) was dissolved in 250 ml. of absolute ethanol and reduced over 0.6 g. of a platinum oxide catalyst at an initial hydrogen pressure of 60 pounds psi. at room temperature. After a total uptake of the theoretical amount of hydrogen, the catalyst was removed by filtration, and the filtrate taken to dryness. The residue was recrystallized several times from a methanol/acetone/ ether mixture and once from acetone along giving 3.4 g. of N (3-amino-4-chlorobenzoyl)-N,N-bis-[-6-(4-cyclohexylmethyl l piperidyl)hexyl] amine dihydrochloride, M.P. 205.4207.6 C. (corn).

EXAMPLE l8 1 N-(4-acetylaminobenzoyl) N,N bis-[6-(4 cyclohexylmethyl-I-piperidyl)hexyl]amine dihydrochloride [1: R is 4-CH C H R is H; R is 4-CH CONHC H CO; Y is (CH2)6; n i8 2] A suspension of 8.4 g. (0.01 mole) of N-(4-aminobenozyl) N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl) hexyllamine dihydrochloride in about 120 ml. of pyridine was treated with 2.65 g. (0.026 mole) of acetic anhydride and warmed on a steam bath for about three hours. The reaction mixture was taken to dryness, the residue extracted with boiling acetone and the combined acetone extracts evaporated to a volume of about 50 ml. The solid which separated was recrystallized once from methanol/ether and once from acetone/methanol to give 5.4 g. of N-(4-acetyla-minobenzoyl)-N,N-bis-[6-(4-cyclohexylmethyl 1 piperidyl)hexyl]amine dihydrochloride, M.P. 185.0-1890 C. (corn).

EXAMPLE 182 N-(3,5 diacetylaminobenzoyl)-N,N-bis-[6-(4-cycl0hexylmethyl-1-piperidyl)hexyl]am ine dihydrvchloride [I2 R is 4-CH C H R2 is R3 is 1% 3,5-(CH CONH) C H CO Y is (CH- n is 2].

A mixture of 9.7 g. (0.013 mole) of N-(3,5-diarninobenzoyl)-N,N-bis-[6-(4-cyclohexylmethyl l piperidyl) hexyllamine dihydrochloride and 5.01 g. (0.05 mole) of acetic anhydride in about 200 ml. of pyridine was heated on a steam bath for one hour, and then taken to dryness in vacuo. The residue was extracted with methanol/acetone and the combined extracts concentrated to a volume 10 of about 200 ml. and diluted with ether. The solid which separated was recrystallized from an isopropanol/ acetone mixture giving 3.9 g. of N-(3,S-diacetylaminobenzoyl)-N, N-bis- 6 4-cyclohexylmethyll -piperidyl hexyl] amine dihydrochloride, M.P. 2250-2260 C. (corn). 0

EXAMPLE 183 N-benzyl-N,N-bis[3-(4-cyclohexylmclhyl I piperidyl) propylJamine [1: R is 4-CH C H R is H; R is C H CH Y is (CH n is 2].

To a slurry of 0.38 g. (0.01 mole) of lithium aluminum hydride in ml. of tetrahydrofuran was added, over a period of about forty-five minutes, a solution of 5.7 g. (0.01 mole) of N-benZoyl-N,N-bis-[3-(4-cyclohexylrnethyl-l-piperidyl)propyl]-amine, in 30 ml. of tetrahydrofuran. The mixture was refluxed for five hours, allowed to stand overnight at room temperature, hydrolyzed by dropwise addition of a solution of 0.08 ml. of water in about 10 ml. of tetrahydrofuran and filtered. The filter was washed with ether, the filtrate taken to dryness,

30 and the residue recrystallized from acetone giving 3.1

g. of N benzyl-N,N-bis-[3-(4-cyclohexylmethyl-1piperidyl)propyl]amine, M.P. 36.8-40.2 C. (corn).

N-benzyl N,N bis-[3-(4 cyclohexylmethyl-l-piperidyl)-propyl]amine reacts with formic acid, acetic acid,

malic acid, fumaric acid, succinic acid, succinamic acid,

tartaric acid, citric acid, lactic acid, benzoic acid, 4-methoxybenzoic acid, phthalic acid, anthranilic acid, l-naphthalenecarboxylic acid, cinnarnic acid, cyclohexanecarboxylic acid, mandelic acid, tropic acid, crotonic acid, 40 acetylene dicarboxylic acid, sorbic acid, Z-furancarboxylic acid, cholic acid, pyrenecarboxylic acid, 2 pyridinecarboxylic acid, 3-indoleacetic acid, quinic acid, sulfamic acid, methanesulfonic acid, isethionic acid, benzenesulfonc acid, p-tolucnesulfonic acid, benzenesulfinic acid, butylarsonic acid, diethylphosphinic acid, p-aminophenylarsinic acid,

phenylstibnic acid, phenylphosphinous acid, methylphosphonic acid, phenylphosphinic acid, hydrofluoric acid, hydrochloric acid, hydrobromic acid, hydriodic acid, perchloric acid, nitric acid, sulfuric acid, phosphoric acid, hydrocyanic acid, phosphotungstic acid, molybdic acid, phosphomolybdic acid, pyrophosphoric acid, arsenic acid, picric acid, picrolonic acid, barbituric acid, boron trifiuoride, and the like, to give, respectively, the formate, acetate, isobutyrate, alpha-mercaptopropionate, malate (or 5 acid malate), fumarate (or acid fumarate), succinate (or acid succinate), succinarnate, tartrate (or bitartrate), citrate (or acid citrate), lactate, benzoate, 4-met-hoxybenzoate, phthalate (or acid phthalate), anthranilate, l-naphthalenecarboxylate, cinnamate, cyclohexanecarboxylate, 6O mandelate, tropate, crotonate, acetylene dicarboxylate, sorbate (or acid sorbate), 2-furancarboxylate, cholate, pyrenecarboxylate, Z-pyridinecarboxylate, 3-indoleacetate, quinate, sulfamate, methanesulfonate, isethionate, benzenesulfonate, p-toluenesulfonate, benzenesulfinate, butylarsonate, diethylphosphinate, p-aminophenylarsinate, phenylstibnate, phenylphosphinate, methylphosphonate, phenylphosphinate, hydrofluoride, hydrochloride, hydrobromide, hydriodide, perchlorate, nitrate, sulfate (or bisulfate), phosphate (or acid phosphate), hydrocyanide, phos- 7 photungstate, molybdate, pho'sphomolybdate, pyrophosphate, arsenate, picrate, picrolonate, barbiturate, and boron trifluoride salts.

EXAMPLES 184-23 3 The following N-(R )-N,N-bis-[ (4-cyclohexyl-rnethyl-l- 17 piperidyl) -lower-alkyl]amines of Formula I [R is 4-OH C H11; R is H; n is 2] listed below in Table 8' were prepared by reduction of the corresponding (R )-amides with lithium aluminum hydride using the manipulative procedure described above in Example 5 183. All melting points are corrected.

13 4-CH C H R is H; R is CH ;'n is 2] listed below in Table 9 were prepared using the manipulative procedure described above in Example 234 by reacting the corresponding N,N-bis- (4-cyclohexylmethyl- 1 -piperidyl -lower-alkyl1amine with formaldehyde in formic acid. All melting points are corrected TABLE 8 Base or Y R Salt M.p. C.) Cryst. frorri- (CHM... CaHsCHz 3HC1.-. 265.0-268.4 Methanol/acetone/ether. H2)o Z-ClC HiCH %gano i;ecetone. 2 1 arm acetone. 4-0106114011 163.8166.0 Methanol/acetone. (CHM... 3,4-CIZCuH3CHg 31101..- 248.5 253.0 Ethanol/acetone.

GIL 4-OH OO5H4CH: Base-.. 33. 8-36.8 Acetone. (CHz)a 4-OHaOO I-IiCHg 3HO1.. 217. 2-218.6 Methanol/acetone. (CHz)3. 3-OFaO6I-I4OH HM. 285.8287.6 Isopropanol/acetone/ether. (CHM... 4-CF3COH4CH2..... 246.8-250.4 Ethanol/acetone/ether. (CHM-.- (CHahCl-ICH; 23l.0233.8 Do. (CHm-.. CH3(CH:)4 fithgnol/iaicetonel 1 et ano ace'one at 101. Acetone. (C Hm. Methanol/acetone. (CHzh-.. CH3(OH2).;. Ethanol/acetone. (CH2)0-.- CHAC m. Methanol/acetone. (CH2)e CHflOHm. Ethanol/acetone.

CHACHmlvlothanol/acetone. C'aHsCHz Ethanol/acetone. C-1H7CH2 D0. CsHuCHn... Methanol/acetone. CsHuCHz Ethanol/acetone. CflHfiOCI'IZCHfl. Acetone. CflHiOGHgCHQ. Mcthanol/acetoue/ether. CH;CH1 Isopropanol/aeetoue. -(CE[ Methanol/acetone.

31-15 DO. CgH Methanol. :1 Methanol/acetone. CzHs Ethanol. C7115 DO.

3H1. Ethanol/acetone. CaHL. 2S7. 2-288. 8 Isopropanol/acetone. 03117.... 81-101... 260. 8264.0 Ethanol/acetone/ether. 04119.... 3H0]... 282.6283.6 Ethanol/acetone. C4119. 3HCl..- 255. 0-2510 Do. C4H 3HC1..- 236.8244.0 Methanol/acetone. C4119 3H C1... 229. 0-231. 0 Methanol/acetone/ether- (CHmOI-I. 3HC1... 235.0-238.0 Methanol/acetone. (CH2)4OH 3H0 249.0-L6 Ethanol/acetone. CaH5(CHa)3. 3E0 287. 4-288. 5 Do. CaHs (C Hfls. 3E0]... 254. (F256. 0 D0. CaHMCHm- Base-.- 57.8-60.0 Acetone. CsHu(CH2)3. 31-101... 279. 2281.0 Ethanol/acetone. CUH11(CH2)3. 3HC 281.0-28L4 DO. condemn- Do. O H CHm Mctlbanollaeetonc.

. o. Acetone. 41-101... 192.0-200.0 Methanol/acetone. 2-HO C-sH4CHn. 3H Cl--- 275. 0-296. 8 Do. .CHKCHQQ. 31-101.-- 247.42520 Do.

Tris eyclohcxanosulfamete salt.

I EXAMPLE 234 TABLE 9 y i y y 1 p pf y Example Y Base or M.P. C.) Cryst. frompropyflamine [1: R is 4-C-H C H R 18 H; R 18 CH Salli 3HC1... 300.0 Ethanol/acetone. Y (CHQB, 2] mas-30% lgdethauollac/etorie.

0 sopr-opano ace one. A solution of 13.8 g. (0.03 mole) of N, N-bis-[3-(4- Methanollacetoue cyclonexylmethyl-1-p1per1dyl)propyl]amine 1n 5 ml. of formic acid was treated with 2.8 ml. (about 0.03 mole) of aqueous formaldehyde. When the initial vigorous re- EXAMPLE 239 action had subsided, the mixture was heated on a steam bath for about eight hours. A slight excess of concentrated hydrochloric acid was added, heating was continued for another five hours, and the mixture was basified with aqueous sodium hydroxide and extracted with chloroform. The combined chloroform extracts were taken to dryness and the residue recrystallized from a hexane/ace tone mixture giving 5.8 g. of N-methy1-N,N-bis-[3-(4- cyclohexylmethyl 1-piperidyl)propyl] amine, M.P. 40.8- 41.8 C. (corn).

EXAMPLES 235-23 8 N-(Z-cyanoethyl) LN bis-[3-(4 cyclohexylmethyl-I- piperidyl)-pf0pyl]czmino [I1 R is 4-CH C H R is H; R is CH CH CN; Y is (CI-1 h; n is 2) (corr.

19 EXAMPLE 240 N-(Z-hydroxyethyl) N,N bis-[6-(4-cycl0hexylmethyl-1- piperidyl) hexyfiam ine trihydrochl-oride [I2 R is 4-CHZCGH1I; R2 is R3 is Y is n is 2] A mixture of 5.43 g. (0.01 mole) of N,N-bis-[6-(4- cyclohexylmethyl-l-piperidyl)hexyl]amine and 0.48 g. (0.01 mole) of ethylene oxide in 150 ml. of dry benzene was heated in an autoclave at l24-129 C. for eight hours and for an additional eight hours at 175-179 C. The reaction mixture was taken to dryness and the residual dark brown viscous oil was triturated with ethanol and a slight excess of ethanolic hydrogen chloride, slurried with acetone and the dark brown gummy solid collected and recrystallized several times from a methanol/ acetone mixture giving 4.6 g. of N-(Z-hydroxyethyl)-N,N-bis-[6 (4-cyclohexylmethy1-1 piperidyl)hexyl]amine trihydrochloride, M.P. 276277 C. (corn).

EXAMPLE 241 N-(4-nitr0benzyl) N,N bis-[6-(4 cyclohexylmethyl-J- piperidyl)-hexyl]amine trihydrochloride [1: R is 4-CH2CH11 R2 is R3 is 4-NO C H CH Y is 2)s; i5

A mixture of 5.43 g. (0.01 mole) of N,N-bis-[6-(4- cyclohexylmethyl-l-piperidyl)hexyl]amine, 2.55 g. (0.015 mole) of 4-nitrobenzyl chloride, and 2.12 g. (0.02 mole) of sodium carbonate in 70 ml. of absolute ethanol was heated under reflux for four hours. The mixture was taken to dryness, the residue dissolved in a benzene/ ether mixture, the organic solution decanted from the solid residue and extracted with dilute hydrochloric acid. The aqueous layer of the resulting three-phase system was discarded, and the middle layer was dissolved in chloroform, extracted with sodium bicarbonate, washed with water, dried and taken to dryness. The residual orange gum was dissolved in a small amount of ethanol and treated with an excess of ethanolic hydrogen chloride. Dilution of the mixture with ether afforded the crude product is solid form which was collected and recrystallized from methanol giving 2.7 g. of N-(4nitrobenzyl)-N,N-bis-[6-(4-cyclohexylmethyl-l-piperidyl) hexyl]amine trihydrochloride, M.P. 231.0233.0 C. (corn).

EXAMPLE 242 N (Z-acetoxybenxyl)-N,N-bis-[6-(4-cycl0hexylmethyl-1- piperidyl)hexyl]amine tri(cyclohexarzesulfamate [Iz R is 4-C H CH R is H; R; is 2-CH COOC H CH Y is (CI-I n is 2] A mixture of 6.9 g. (0.01 mole) of N-(2-hydroxybenzyl) N,N bis-[6-(4-cyclohexylmethyl-1-piperidyl) hexylyamine and 7.0 ml. (0.07 mole) of acetic anhydride in 50 ml. of benzene was heated under reflux for seven hours, cooled, filtered to remove a small amount of a solid which has separated, and the filtrate washed with 5% sodium carbonate, then with water and dried. On evaporation of the organic solution to dryness, conversion of the residual oil to the tri(cyclohexanesu'lfamate) salt, and recrystallization of the latter from acetone, there was obtained 6.9 g. of N-(2-acetoxybenzyl -N,N-bis-[6-(4-cyclohexylmethyl 1 piperidyl)hexyl] amine tri(cyclohexar1esulfamate), M.P. 134043710 C. (corn).

EXAM PLES 243-272 By following the manipulative procedure described above in Example 241, substituting for the N,N-bis-[fi- (-4-cyclohexylmethyl-l-piperidyl)hexyl]amine used therein, a molar equivalent amount of an appropriate [(substituted-l-piperidyl)-loWer-alkyl]amine, there can be obtained the N-(4-nitrobenzyl) N-[ (substituted-l-piperidyl lower-alkyl1amines of Formula I (R is 4-NO C H CH n is 1) listed below in Table 10.

TABLE 10 Example Y R1 R;

4-CONH: H H H H (f) H HCHO H 4-NHCOCH(CZH5)CH CH H 3-CONHCH2CH2CI'I2CH3. H 4-C0NC5H10 H 255 (0512):. irCONOiHg H I 256 (0111);- 4-OaH NCH3 H I 257 (0112);. 4'CQH5NCOCH3 H l 258 (CHzh... 4-CoH5NCHzCHzCsH5 H I (CHz)4 4-CaH5NCOCaH5 H (CHzh 4-(1-methyl-3-piperidyl)NCH H (CHM. 4-(l-acetyl-3-piperidyDN OH; H (CH2) ;i 4 (l-phenethyl3-piperidyl)N OH; H (CH2)3 4-(1-benzoyl-3-piperidyDN CH H I 264 (CH7)3... 4-CsH5NCONHz H l 265 (CH2):4. 4-CaH5NCONHCH: H

l (0111);. 4-CuH5NCON(CI-Ia)z H l (CHQ H 4-C0H5NCOOC7H5 H 4(-mothyl-l-piperazinyl) H 4-(4-acetyl-1-piperazlnyl) H 4- (4-phenyl-1-piperazinyl) H 4-(4-phenethyl1-piperazinyl) H 444-benzoyl-l-piperazinyl) H l 2,6( CH3) 2 2 t By following the manipulative procedure described above in Example .114, substituting for the N,N-bis-[3- (4 cyclohexylmethyl l-piperidyl)propyl]amine used therein, a molar equivalent amount of an appropriate N,N bis [(-subst'ituted-1-piperidyl) l0wer-alkyl]amine and reducing the N benzoyl N,N-bis-[(substituted-1- piperidyl)-lower-alkyl]amines thus obtained with lithium aluminum hydride according to the manipulative procedure described above in Example 183, there can be obtained the N benzyl-N,N-bis[(substituted-l-piperidyl)- lower-alkyH-amines of Formula I (R is C H CH n is 2) listed below in Table 11.

TABLE 11 Example R1 4-CHzCoH5 4-(CH3):CH 4-CeH5O 4-(2-naphthylO-) 4-CaH5CHzCH2O.

4-[ (2-napl1thyl)O-(CHn)2] 2-naphthylNCH (CH2)5- 4(4-C5H4N)NCH (CHz)a 4-(2-isoindolinyl) (0112):. c. 4-(1pyrrolid (CHm. 4-(l-piperidyl) mmmmmmmmmmmmmmm Our new N-lower-alkyland N-substituted-lower-alkyl- N-[( l-piperidyl)lower-alkyl]amines of Formula I showed anti inflammatory activity in one or more of two difierent test procedures, viz., inhibition of granuloma pouch form ation in rats and inhibition of para-influenza (Sendai strain) virus-induced lung inflammation in mice. Data obtained for representative compounds of the series are given in Table '12 which follows. The activities are given in terms of the minimum dose (MIND) which is defined as the smallest dose, expressed in milligrams per kilogram of body weight, producing 30% inhibition of the inflammation in the lung inflammation test and 40% inhibition in the granuloma pouch test. The symbols GJP. and LJI. represent the tests named above, namely the granuloma pouch and lung inflamarntion tests, respectively, while the designations 5.0. and p0. represents subcutaneous and peroral routes of administration, respectively.

TABLE 12 Example G.P. L.I.

183 0.25 (5.0.) 6.25 (5.0.) 100 (p.o.) 0.40 (5.0.) 6.25 (5.0.) 6.25 (5.0.) 25 (5.0.) 100 (p.o.) 6.25 (5.0.) 100 (p.o.) 1.56 (5.0.) 1.56 (5.0.) 6.25 (5.0.) 6.25 (5.0.) 25 (p.o.) 1.56 (5.0.) 100 (p.o.) 6.25 (5.0.)

6.25 (5.0.) 1.56 (5.0.) 1.56 (5.0.) 25 (p.o.) 6.25 (5.0.) 25 (p.o.) 1.56 (5.0.) 212 0.40 (5.0) 1.56 (5.0.) 25 (p.o.) 6.25 (p.o.) 213 6.25 (5.0.) 214 0.40 (5.0.) 6.25 (5.0.)

6.25 (p.o.) 25 (p.o.) 215 1.56 (5.0.) 210 25 (p.o.) 6.25 (5.0.) 218 1 40 (5.0)

i5 i i 239 100 .o. 5 5.0.

p 100 (p.o

The compounds of Formula I have also been shown to possess coronary dilator activity when tested in the isolated rabbit heart. Coronary dilator activity data so-obtained for representative compounds of the series are given in Table 13 below. The activities are expressed either in terms of the Effective Dose (ED or in terms of the percent dilatation, at a given dose level, the doses in both oases being expressed in terms of the dose per heart.

TABLE 13 EX ample Activity 189 ED =10.8 meg; 1315% of papaverine. 190 12% dilatation at 50 mg. 20 0 13% dilatation at 50 mg. 20 5 1 2% dilatation at 100 mg. 206 ED =6=6 rncgn; 2152% of papaverine. 209 19% dilatation at 100 mg. 2 14 54% dilatation at 100 mg. 215 ED =S.7 meg; 2500% of papaverine. 216 ED =4.2 mcg.; 3380% of papaverine. '217 ED =8.2 mcg.; 1732% of papaverine. 2'18 ED i1 mcg.; 1420% of papaverine. 2.34 21% dilatation at 50 mg.

The compounds of Formula I have also been shown to have psychomotor depressant activity as determined in mice using standard activity cages. Psychomotor depressant activity so-obtained for representative compounds of the series are given below in Table 14. The data are given in terms of the percentage decrease in the animals activity at a particular dose level.

. TABLE 14 Example: Activity 208 71% decrease at 100 mg./k g. (p.o.). 209 decrease at 300 mg./kg. (p.o.). 213 58% decrease at mg./kg. (p.o.). 214 75% decrease at 10O mg./kg. (p.o.). 215 76% decrease at 100 mg./kg. (p.o.). 217 86% decrease at 300 mg./kg. (p.o.). 218 71% decrease at 300 mg./kg. (p.o.). 234 71% decrease at 300 rug/kg. (p.o.). 235 69% decrease at 10 mg./kg. (p.o.). 236 65% decrease at 100 rug/kg. (p.o.). 238 72% decrease at 300 mg./kg. (p.o.).

The compounds of Formula I have also been shown to possess anthelmintic activity when administered orally to Swiss mice infected by the tapeworm, Hymenolepis mum, and the pinworm, Aspicularis tetrapzera. Data 50- obtained with representative compounds are given below in Table 15 and are expressed in terms of the dose, in mg./ kg./ day administered two times a day for four days, required to clear all of the animals in the test group of each of the test organisms.

TABLE 15 Dose (mg./kg./day) Asp. tetraptera Example Hy. mma

The compounds can be prepared for use by dissolving under sterile conditions a salt form of the compounds in Water (or an equivalent amount of a non-toxic acid if the free base is used), or in a physiologically compatible aqueous medium such as saline, and stored in ampoules for intramuscular injection. Alternatively, they can be incorporated in unit dosage form as tablets or capsules for oral administration either alone or in combination with suitable adjuvants such as calcium carbonate, starch, lactose, talc, magnesium stearate, gum acacia, and the like. Still further the compounds can be formulated for oral administration in aqueous alcohol, glycol or oil solutions or oil-water emulsions in the same manner as conventional medicinal substances are prepared. When used as hypotensive agents, they are formulated and used in the same manner as conventional hypotensive agents, such as reserpine preparations, and indeed can be used advantageously in combination with such hypotensive agents.

We claim:

1. A compound of the formula wherein R is unsubstituted-carbamyl, N-lower-alkylcarbamyl, N,N-di-lower-alkylcarbamyl, piperidinocarbonyl, pyrrolidinocar-bonyl, hydroxy, lower-alkoxy, phenoxy, naphthoxy, phenyl-lower-alkoxy, naphthyl-lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, phenoxylower-alkyl, naphthoXy-lower-alkyl, lower-alk-anoylamino, phenyl-lower-alkyl, cycoakyl-lower-alkyl, or the group wherein R is phenyl, naphthyl, pyridyl, 3- or 4-piperidyl substituted on the nitrogen atom by lower-alkyl, loweralkanoyl, phenyl-lower-alkyl, or henzoyl; R is loweralkyl, lower-alkanoyl, phenyl-lower-alkyl, benzoyl, carbamyl, N-lower-alkyl-carbamyl, N,N-di-lower-alkylcarbamyl, or carbo-lower-alkoxy; or R and R taken together with the nitrogen atom to which they are attached form a heterocyclic ring selected from the group consisting of isoindolinyl, pyrrolidyl, piperidyl, or piperazinyl substituted on the 4-nitrogen atom by lower-alkyl, loweralkanoyl, phenyl, phenyl-lower-alkyl, or benzoyl; R is hydrogen or from one to five lowe-r-alkyls; R is phenylloweralkyl, lower-alkyl, cycloalkyl-lower-alkyl, hydroxymethyl-cycloalkylmethyl, phenoXy-lower-alkyl, hydroxylower-alkyl, cyano-lower-alkyl, or divalent lower-alkylene joining two of the (l-piperidyl)-lower-alkylamino radicals together; Y is lower-alkylene; and n is one of the integers 1 and 2, the third valence on the amino nitrogen atom being taken up by a hydrogen atom when n is 1.

2. A compound according to claim 1 wherein R is cycloalkyl-lower-alkyl; R is hydrogen; R is lower-alkyl; and n is 2.

3. A compound according to claim 1 wherein R is cycloalkyl-lower-alkyl; R is hydrogen; R is phenyllower-alkyl; and n is 2.

4. A compound according to claim 1 wherein R is cycloalkyl-lower-alkyl; R is hydrogen; R is hydroxylower-alkyl; and n is 2.

5. A compound according to claim 1 wherein R is cycloalkyl-lo-wer-alkyl; R is hydrogen; R is hydroxymethylcycloalkylmethyl; and n is 2.

6. N-methyl N,N-bis-[5-(4-cyclohexylrnethyl 1-piperidyl)pentyl]a-mine according to claim 2 wherein R is 4-cyclohexylmethyl; R is methyl; and Y is 1,5-pentylene.

7. N-ethyl N,N-bis-[3-(4-cyclohexylmethyl l-pipe ridyl)propyl]amine according to claim 2 wherein R is 4cyclohexylmethyl; R is ethyl; and Y is 1,3-propylene.

8. N-butyl N,Nbis-[3(4-cyclohexy1methyl l-piperidyl)propyl]amine according to claim 2 wherein R is 4-cyclohexylmethyl; R is butyl; and Y is 1,3-propylene.

9. N-butyl N,N-'bis[6-(4-cyclohexylmethyl l-piperidyl)hexyl]amine according to claim 2 wherein R is 4-cyclohexylrnethyl; R is butyl; and Y is 1,6-hexylene.

10. N-pentyl N,N-bis-[6-(4-cyclohexylmethyl l-pipe'ridyl)hexyl]amine according to claim 2 wherein R is 4-cyclohexylmethyl; R is pentyl; and Y is 1,6-hexylene.

11. N-benzyl N,N-bis-[6-(4-cyclohexylmethyl l-pipe-ridyl)hexyl] amine according to claim 3 wherein R is 4-cyclohexylmethyl; R as phenyl-lower-alkyl is unsubstituted benzyl; and Y is 1,6-hexylene.

12. N-(4-chlorobenzyl) N,N-bis [6-(4-cyclohexylmethyl 1-piperidyl)heXyl]-amine according to claim 3' wherein R is 4-cyclohexylmethyl; R as phenyl-loweralkyl is benzyl bearing a 4-chloro substituent; and Y is 1,6-hexylene.

13. -N (4-trifiuoromethyl-benzyl) N,N-bis [6-(4- cyclohcxylmethyl 1-piperidyl)hexy1] amine according to claim 3 wherein R is 4-cyclohexylmethyl; R as phenyllower-alkyl is benzyl bearing a 4-trifiuoromethyl substituent; and Y is 1,6-hexylene.

14. N-(3-pheny1propyl) N,N bis [3-(4-cyclohexylmethyl l-piperidyl) propyl1amine according to claim 3 wherein R is 4-cyclohexylmethyl; R as phenyl-loweralkyl is unsubstituted 3-phenylpropyl; and Y is 1,3-propylene.

15. N-(4-aminobenzyl) N,N-bis [6-(4-cyclohexylmethyl 1-piperidyl)hexyl]amine according to claim 3 wherein R is 4-cyclohexylmethyl; R as phenyl-loweralkyl is benzyl bearing a 4-amino substituent; and Y is 1,6-hexylene.

16. N-(2-hyd roxyethyl) N,N-bis [6-(4-cyclohexylmethyl 1-piperidyl)hexyl]amine according to claim 4 wherein R is 4-cyclohexylmethyl; R is 2-hydroxyethyl; and Y is 1,6-hexylene.

17. N-(4-hydroxybutyl) LN-bis [6-(4-cyclohexylmethyl 1-piperidyl)hexyl]amine according to claim 4 wherein R is 4-cyclohexylrnethyl; R is 4-hydroxybutyl; and Y is 1,6-hexylene.

l8. N-(2-hydroxymethylcylclohexylmethyl) N,Nbis- [6-(4 cyclohexylmethyl 1-piperidyl)hexyl]amine according to claim 5 wherein R is 4-cyclohexylmethyl; R is 2-hydroxymethyl-cyclohexylmethyl; and Y is 1,6-hexylene.

References Cited UNITED STATES PATENTS 2,662,885 12/1953 Schule'r 260243 2,928,831 3/1960 Surrey 260293 2,945,032 7/1960 Marxer 260-293 2,946,793 7/1960 Michales et a1. 260294.76 3,052,684 9/1962 Adickes et al. 260 -2943 3,092,636 6/1963 Heinzelmak 260-2947 3,234,276 2/1966 -Petracek 260-294 3,230,520 3/1966 Provsdij-Hartzema 260-294 3,285,905 11/1966 Elslager et a1. 2602 93 NORMA S. MILESTONE, Acting Primary Examiner.

A. D. SPEVACK, Assistant Examiner.

UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3,371,093 February 27, 1968 Bernard L. Zenitz et al.

It is hereby certified that error appears in the above numbered patent requiring correction and that the said Letters Patent should read as corrected below.

Column 1, line 60, "alkanol" should read alkanoyl Column 4, line 63, "[l" should read [(l- Column 6, line 73, "acid'adidtion" should read acid-addition Column 8,

Table 1, second column, line 2 thereof, "4-CONYC H should read 4CONHC H Column 9, Table 3, third column, line 38 thereof, "4(6-" should read 4-(4- Column 10, Table 4, third column, line 15 thereof, "4-(2-napthy1-CH CH -O" should read 4(2napthyl-CH CH -O) same Table 4, third n n column, lilne 20 thereof, 4 C H NCH CH C H should read H 4-C H NCH CH C H same Table 4, third column, line 36 thereoQ, "4%4acetyl l piperazinyl)" should read 4-(4- acetyl-l-piperazinyl) Column 15, line 19, "N(3,5dinl trobenzoyl N" should read N-(3,5dinitrobenzoyl)-N line 47, "along" should read alone Column. 16, line 27 "O 08" should read 0.8- Columns 17 and 18 Table 8 fifth column, line 19 thereof, "480.4" should read 280.4

--; same Table 8, fifth column, line 30 thereof, "291,2" should read "91 .2 same Table 8 second column, line 38 thereof, "(CHU should read (CH same Table 8, first column,

line 47 thereof, "30" Should read Z30 Column 19, line 41, "is" should read in line 49, "(cyclohexanesulfamate" should read [cyclohexanesulfamate) Signed and sealed tnis 9th day of September 1969.

(SEAL) Attest:

EDWARD M.FLETCHER,JR. WILLIAM E. SCHUYLER,JR. Attestlng Officer Commissioner of Patents 

